A Phase 1 Investigator-and-subject Blind, Randomized, Placebo Controlled, Parallel Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Oral Doses Of Pf-06648671 On Aβ Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology
Overview
- Phase
- Phase 1
- Intervention
- PF-06648671
- Conditions
- Healthy Subjects
- Sponsor
- Pfizer
- Enrollment
- 22
- Locations
- 2
- Primary Endpoint
- CSF Aβ40 and Aβ42 concentration at maximum change from baseline
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This is phase 1 investigator-and-subject blind, sponsor open, randomized, placebo controlled, parallel study in healthy subjects to evaluate the pharmacodynamics effect of single oral doses of PF-06648671 on CSF Aβ concentrations using serial CSF sampling methodology.
Detailed Description
This study is investigator-and-subject blind, sponsor open, randomized, placebo-controlled, parallel study in healthy subjects to evaluate central (CSF) and peripheral (plasma) pharmacodynamics effects (Abeta) over 36 hours post single doses of PF-06648671. Two cohorts will be run in sequential. the first cohort is to evaluate the Abeta effect at top dose of 300 mg PF-06648671 and second cohort is to evaluate the Abeta effect at top dose (if more subjects are required) and/or 1-2 lower doses
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy male and/or female subjects of non childbearing potential
- •BMI of 17.5 to 30.5 kg/m2 and a total body weight \>50 kg (110 lbs)
- •Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study.
Exclusion Criteria
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated asymptomatic, seasonal allergies at the time of dosing)
- •Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study medication (whichever is longer)
- •Subjects with a history of significant active bleeding, coagulation disorder or clinically significant finding on prothrombin time/ partial thromboplastin time/International Normalized Ratio (PT/PTT/INR) at Screening
- •Subjects with lower spinal malformations (on physical examination), local spinal infection, or other abnormalities that would exclude puncture (LP)
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study
Arms & Interventions
PF-06648671 High dose group
subjects receive a single oral dose of PF-06648671 at 300 mg
Intervention: PF-06648671
PF-06648671 Low dose group
Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
Intervention: PF-06648671
Placebo group
Subjects receive matching placebo
Intervention: Placebo
PF-06648671 Low dose group (2)
Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
Intervention: PF-06648671
Outcomes
Primary Outcomes
CSF Aβ40 and Aβ42 concentration at maximum change from baseline
Time Frame: 0-36 hours postdose
Secondary Outcomes
- Maximum Observed Plasma Concentration (Cmax)(0-72 hours postdose)
- Area Under the Curve from Time Zero to Last Quantifiable Plasma Concentration (AUClast)(0-72 hours postdose)
- Plasma Decay Half-life (t1/2)(0-72 hours postdose)
- Apparent Oral Clearance (CL/F)(0-72 hours postdose)
- Area Under the Curve from Time Zero to Last Quantifiable Concentration in CSF (CSF AUClast)(0-36 hours postdose)
- Number of participants with lab test values of potential clinical importance(0-2 weeks)
- Number of participants with AEs and SAEs(0-2 weeks)
- Time to Reach Maximum Observed Plasma Concentration (Tmax)(0-72 hours postdose)
- Maximum Observed CSF Concentration (CSF Cmax)(0-36 hours postdose)
- Area Under the Curve From Time Zero to Extrapolated Infinite Time in CSF (CSF AUCinf)(0-36 hours postdose)
- supine vital sign(0-2 weeks)
- Electrocardiogram (ECG)(0-2 weeks)
- CSF Aβ37, Aβ38 and Aβtotal Concentration(0-36 hours postdose)
- Area Under the Curve From Time Zero to Extrapolated Infinite Time in Plasma (AUCinf)(0-72 hours postdose)
- Apparent Volume of Distribution (Vz/F))(0-72 hours postdose)
- CSF Decay Half-life (CSF t1/2)(0-36 hours postdose)
- Plasma Aβ40, Aβ42 and Aβtotal(0-72 hours postdose)